- Home
- SNBR vs ENGN Comparison
SNBR vs ENGN Comparison
Compare SNBR & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNBR
- ENGN
- Stock Information
- Founded
- SNBR 1987
- ENGN 1999
- Country
- SNBR United States
- ENGN Canada
- Employees
- SNBR N/A
- ENGN N/A
- Industry
- SNBR Home Furnishings
- ENGN
- Sector
- SNBR Consumer Discretionary
- ENGN
- Exchange
- SNBR Nasdaq
- ENGN Nasdaq
- Market Cap
- SNBR 261.1M
- ENGN 293.1M
- IPO Year
- SNBR 1998
- ENGN N/A
- Fundamental
- Price
- SNBR $16.74
- ENGN $5.83
- Analyst Decision
- SNBR Hold
- ENGN Strong Buy
- Analyst Count
- SNBR 3
- ENGN 8
- Target Price
- SNBR $12.83
- ENGN $30.38
- AVG Volume (30 Days)
- SNBR 398.2K
- ENGN 200.8K
- Earning Date
- SNBR 10-30-2024
- ENGN 12-19-2024
- Dividend Yield
- SNBR N/A
- ENGN N/A
- EPS Growth
- SNBR N/A
- ENGN N/A
- EPS
- SNBR N/A
- ENGN N/A
- Revenue
- SNBR $1,734,997,000.00
- ENGN N/A
- Revenue This Year
- SNBR N/A
- ENGN N/A
- Revenue Next Year
- SNBR $1.68
- ENGN N/A
- P/E Ratio
- SNBR N/A
- ENGN N/A
- Revenue Growth
- SNBR N/A
- ENGN N/A
- 52 Week Low
- SNBR $8.13
- ENGN $4.42
- 52 Week High
- SNBR $20.75
- ENGN $18.40
- Technical
- Relative Strength Index (RSI)
- SNBR 47.89
- ENGN 26.75
- Support Level
- SNBR $18.36
- ENGN $5.68
- Resistance Level
- SNBR $20.00
- ENGN $6.55
- Average True Range (ATR)
- SNBR 1.35
- ENGN 0.69
- MACD
- SNBR -0.26
- ENGN -0.24
- Stochastic Oscillator
- SNBR 26.86
- ENGN 6.99
About SNBR Sleep Number Corporation
Sleep Number Corp. is a wellness technology company engaged in the design, manufacturing, marketing and distribution of sleep solutions. The Company generates revenue by marketing and selling its smart beds directly to new and existing customers through its vertically integrated, exclusive, direct-to-consumer retail touch points including Stores, Online, Phone, and Chat (Total Retail). The products offered by the company are Mattresses, Bedding, Pillows and Furniture.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.